| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.01. | Vaxil Bio Ltd (2): Vaxil Bio 1,244,441-share private placement | 2 | Stockwatch | ||
| 04.12.25 | Vaxil Bio Ltd (2): Vaxil Bio closes $140,000 private placement | 1 | Stockwatch | ||
| 04.12.25 | Vaxil Bio completes $140,000 private placement, announces board changes | 3 | Investing.com | ||
| 04.12.25 | Vaxil Bio Ltd.: Vaxil Announces Close of Previously Announced Non-Brokered Private Placement and Update on Board of Directors | 1 | GlobeNewswire (USA) | ||
| 24.11.25 | Vaxil Bio revises private placement terms, seeks to raise $350,000 | 2 | Investing.com | ||
| 24.11.25 | Vaxil Bio Ltd.: Vaxil Announces Update on Non-Brokered Private Placement | 2 | GlobeNewswire (USA) | ||
| 30.10.25 | Vaxil Bio Ltd (2): Vaxil Bio arranges $350,000 private placement | 2 | Stockwatch | ||
| VAXIL BIO Aktie jetzt für 0€ handeln | |||||
| 29.10.25 | Vaxil Bio Ltd.: Vaxil Announces Non-Brokered Private Placement | 1 | GlobeNewswire (USA) | ||
| 06.05.25 | Vaxil Bio Ltd.: Share Consolidation | 359 | GlobeNewswire (Europe) | Not for distribution by US newswire or in United States TORONTO, May 06, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. ("Vaxil" or the "Company") (TSX VENTURE: VXL), is pleased to make the following updates... ► Artikel lesen | |
| 03.04.25 | Vaxil Bio Ltd.: Vaxil: Management and Operational Update | 206 | GlobeNewswire (Europe) | Not for distribution by US newswire or in United States NESS-ZIONA, Israel, April 03, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. ("Vaxil" or the "Company") (TSX VENTURE: VXL), is pleased to make the... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 50,26 | +17,17 % | Moderna: Kombi-Impfung für Grippe und Covid erhält Zulassung | Gute Nachrichten für Moderna: Die EU-Arzneimittelbehörde EMA hat grünes Licht gegeben für den ersten Kombi-Impfstoff gegen Corona und Grippe. Der Wirkstoff solle für Menschen ab 50 Jahren zugelassen... ► Artikel lesen | |
| QIAGEN | 40,875 | +0,43 % | Shortseller-Positionen aktuell: freenet, Gerresheimer, Hypoport, Qiagen, Renk, Suss MicroTec, TeamViewer | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| BIONTECH | 89,00 | +2,59 % | BioNTech Aktie: Die Wende naht! Golden Cross! | © Foto: 2026 BioNTech SE. Alle Recht vorbehalten.Fast wie in der Serie "Game of Thrones", wo der Winter naht, könnte bei BioNTech die Wende nahen. Nach dem Kursrausch in der Corona-Ära folgte der brutale... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 12,630 | +25,17 % | Needham lowers Day One Biopharmaceuticals price target on costs | ||
| ADMA BIOLOGICS | 16,450 | -0,78 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| KYMERA THERAPEUTICS | 86,46 | -4,05 % | Kymera auf TD Cowen Konferenz: Strategische Einblicke in Medikamenten-Pipeline und Partnerschaften | ||
| EVOTEC | 5,652 | +6,56 % | Evotec Aktie: Kann man "diesem Braten wirklich trauen"? | © Foto: Julia Koblitz auf Unsplash (Symbolbild)Neue Aufträge, ein Sparprogramm und frische Analystenkommentare. Die Evotec-Aktie sendet wieder Lebenszeichen. Doch wer die Geschichte dieses Hamburger... ► Artikel lesen | |
| ARCELLX | 114,29 | +0,25 % | Weekly Buzz: MGNX's LINNET Trial On Hold; Eton Pharmaceuticals, ALUR Get FDA Nod; GILD Snaps Up ACLX | FOSTER CITY (dpa-AFX) - This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results... ► Artikel lesen | |
| ERASCA | 15,050 | +4,55 % | Erasca, Inc. (ERAS): A Bull Case Theory | ||
| TYRA BIOSCIENCES | 35,280 | +8,49 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,305 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen | |
| OCUGEN | 1,670 | +5,13 % | Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results | Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial-the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients-was completed. Topline Phase 3 data expected... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,050 | +1,81 % | Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street | $100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,690 | +6,49 % | Recursion Pharmaceuticals: Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinical... ► Artikel lesen | |
| IMMUNITYBIO | 7,992 | -7,20 % | Piper Sandler raises Immunitybio stock price target on revenue growth |